1 simultaneously with challenging nymphs and
1 week thereafter.
2 d six HIV-1LAI envelope immunizations and
10 weeks thereafter acquired HIV-1 infection through a high
3 acebo every 4 weeks for 7 doses and every
12 weeks thereafter until a treatment discontinuation crite
4 12 months after randomisation, and every
12 weeks thereafter until study drug discontinuation.
5 seline, weeks 4, 7, 10, and 24, and every
12 weeks thereafter up to 2 years, irrespective of disease
6 eks, or 200 mg at weeks 0 and 4 and every
12 weeks thereafter) through week 40, placebo, or adalimuma
7 8 weeks, 50 mg at weeks 0 and 4 and every
12 weeks thereafter, 100 mg every 8 weeks, or 200 mg at wee
8 selkumab (5 mg at weeks 0 and 4 and every
12 weeks thereafter, 15 mg every 8 weeks, 50 mg at weeks 0
9 pulation, assessed at screening and every
12 weeks thereafter.
10 ery 6 weeks up to week 48, and then every
12 weeks thereafter.
11 treatment from day 1 of cycle 1 and every
12 weeks thereafter.
12 which they continued at week 28 and every
12 weeks thereafter.
13 , or placebo at week 0, week 4, and every
12 weeks thereafter.
14 8 weeks for the first 6 months and every
12 weeks thereafter.
15 baseline (b; n = 472), week 9, and every
12 weeks thereafter.
16 uring leaf flush and did not vary for the
19 weeks thereafter when leaves remained active.
17 orming units/mL), then in week 4 and every
2 weeks thereafter (10(8) plaque-forming units/mL).
18 se), and 7 (full dose) and then once every
2 weeks thereafter for 20 weeks.
19 t 6-8 weeks of age (pre-plaque), and every
2 weeks thereafter until all mice were at least 16 weeks o
20 th, and meetings with the study team every
2 weeks thereafter, for the duration of the circumcision c
21 and 3 infusions of 250 million cells every
2 weeks thereafter; total infusion period, 50 days).
22 rtical contusion and persists for at least
2 weeks thereafter.
23 ays without significant changes during the
2 weeks thereafter.
24 at baseline, week 12, week 24, and every
24 weeks thereafter, and potential cases of new-onset diabe
25 ent for 48 weeks and were followed up for
24 weeks thereafter.
26 efore treatment (bIgE) with omalizumab and
4 weeks thereafter (w4IgE).
27 d by 1 week of rest, then weekly x 3 every
4 weeks thereafter (63 patients), or to fluorouracil (5-FU
28 for 16 weeks (cycles 3-6), and then every
4 weeks thereafter (cycle 7 and higher).
29 ntramuscularly at weeks 0, 2, 4, and every
4 weeks thereafter until week 44.
30 owed by 250 mg on days 15 and 28 and every
4 weeks thereafter, and either lapatinib 1,500 mg or place
31 ds) will be measured at baseline and every
4 weeks thereafter.
32 10 mg/kg) on days 1, 15, and 29 and every
4 weeks thereafter.
33 were at baseline, weeks 2 and 4, and every
4 weeks thereafter.
34 erence were measured at baseline and every
4 weeks thereafter.
35 were scanned at 1 month of life and every
4 weeks thereafter.
36 ty was assessed at weeks 2 and 4 and every
4 weeks thereafter; tumor response was evaluated every 8 t
37 placebo for 2 weeks and were followed for
4 weeks thereafter.
38 ed estrogen therapy and every 6 weeks for
48 weeks thereafter.
39 c tumors (MIA PaCa-2) were subsequently (4-
5 weeks thereafter) injected with saline (control), gemcit
40 were repeated at 4 and 8 weeks, and every
5 weeks thereafter.
41 , and follow-up images were acquired every
6 weeks thereafter until tumor progression or death.
42 re assessed at baseline, week 9, and every
6 weeks thereafter using the European Organisation for Res
43 were given at weeks 0, 2, and 6, and every
8 weeks thereafter through week 46.
44 of placebo at weeks 2 and 6 and then every
8 weeks thereafter until week 46 (group I), repeat infusio
45 reatment was assessed at week 12 and every
8 weeks thereafter.
46 eight) at weeks 1, 3, 7, and 14, and every
8 weeks thereafter.
47 to 21 weeks after randomisation, and every
8 weeks thereafter.
48 re obtained routinely at 4 weeks and every
8 weeks thereafter.
49 ons of the same dose were given every 4 or
8 weeks thereafter on a background of a stable dose of met
50 iweekly from weeks 4 to 12, and every 4 to
8 weeks thereafter.
51 sual acuity protocol at baseline and every
9 weeks thereafter until no further improvement in visual
52 ere assessed at day 1 of cycles 1-3, every
9 weeks thereafter, at the treatment discontinuation visit
53 sed every 6 weeks until month 18 and every
9 weeks thereafter.
54 initial dose 400 mg/m(2); 250 mg/m(2) once
a week thereafter).
55 Eight weeks thereafter, a postmortem examination was performed
56 ber of animals died at birth or within a
few weeks thereafter.
57 One week thereafter, the MI+CSD group and 10 animals without
58 e first 2 years of treatment and 20 U/m2
per week thereafter, 3 untreated children were lost to long-
59 160 days and by a mean of 1.9 cells/mm3
per week thereafter (P < 0.01).
60 mg at week 4; and 1200 mg given every
second week thereafter as maintenance dosing.
61 Six weeks thereafter, 2 of 5 animals were given an intraderm
62 e in an experience-dependent manner for
some weeks thereafter.
63 Two weeks thereafter, ovariectomized and proestrus sham-ovar
64 ardiac-transplantation surgery and every
two weeks thereafter, for a total of five doses, or generali